These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6094427)

  • 21. [Interaction of cefotaxime and normal human serum in the bacteriocidal process against strains of Escherichia coli producing surface K1 antigen].
    Franiczek R; Jankowski S
    Med Dosw Mikrobiol; 1993; 45(1):61-4. PubMed ID: 8231445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative evaluation of the antibacterial activity of cefotaxime and cephalotin by using an automated antimicrobial susceptibility determination system].
    Concia E; Marone P; Dos Santos C; Bono L
    Quad Sclavo Diagn; 1982 Jun; 18(2):223-32. PubMed ID: 6300953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of serum cefotaxime levels by HPLC with serum bacteriostatic and bactericidal levels.
    Spicer WJ; Franklin JC; Spelman DW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():109-11. PubMed ID: 6094428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefotaxime: pharmacokinetics and in vitro antibacterial activity of serum and urine in normal human volunteers.
    Plouffe JF; Perkins RL; Fass RJ; Prior RB; Bernstein B; Ho I
    Chemotherapy; 1983; 29(2):73-9. PubMed ID: 6301775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT; Prignano G; Iegri F; Lorenzi A
    Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro activity of ceftriaxone against clinical bacterial isolates in Nigeria.
    Obaseiki-Ebor EE; Afonya TC; Oyaide SM
    Chemotherapy; 1985; 31(2):130-7. PubMed ID: 3872779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
    Zarakolu P; Metan G; Hasçelik G; Akova M
    Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefotaxime kinetics in plasma and synovial fluid following intravenous administration in horses.
    Orsini JA; Moate PJ; Engiles J; Norman T; Poppenga R; Benson CE; Boston RC
    J Vet Pharmacol Ther; 2004 Oct; 27(5):293-8. PubMed ID: 15500566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of cefotaxime and latamoxef for Escherichia coli bacteremia and meningitis in newborn rats.
    Kim KS; Manocchio M; Bayer AS
    Chemotherapy; 1984; 30(4):262-9. PubMed ID: 6086247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of cefotaxime and amikacin against 14,272 gram-negative bacteria from clinical samples in the period 1980 to 1985.
    Dámaso D; Sánchez-Moreno MP; Martínez-Martínez L; Mesa E; Portero F; Mendaza P; Daza RM
    Drugs; 1988; 35 Suppl 2():1-5. PubMed ID: 3396470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect.
    Ravizzola G; Bonfanti C; Savoldi E; Turano A
    Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field].
    Toyonaga Y; Hatakeyama K; Yamori K; Sakaguchi N; Nakano K; Yamazaki M; Sugita M; Hori M
    Jpn J Antibiot; 1992 Jan; 45(1):48-73. PubMed ID: 1495196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of netilmicin, amikacin, ceftazidime and cefotaxime on the adhesive properties of microorganisms isolated from newborn infants].
    Kushnareva MV
    Antibiot Khimioter; 2000; 45(7):17-21. PubMed ID: 10987103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1984 May; 37(5):791-801. PubMed ID: 6090721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Microbiological evaluation of the antibacterial activity of cefotaxime in comparison with other cephalosporins].
    Concia E; Marone P; Verani D; Marino P
    Boll Ist Sieroter Milan; 1982; 61(4):300-8. PubMed ID: 6100233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
    Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S
    Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative antibacterial effects of amoxycillin, amoxycillin/clavulanic acid and cefotaxime against Enterobacteriaceae as determined by turbidimetry, morphology and viable count.
    Wilson JM; Hunter PA
    Chemotherapy; 1986; 32(2):118-25. PubMed ID: 3516591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T; Kawana R
    Jpn J Antibiot; 1988 May; 41(5):594-601. PubMed ID: 3216482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.
    Stone JW; Linong G; Andrews JM; Wise R
    J Antimicrob Chemother; 1989 Feb; 23(2):221-8. PubMed ID: 2708180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temocillin. In vitro antibacterial activity.
    Slocombe B; Cooper CE; Griffin KE; White AR
    Drugs; 1985; 29 Suppl 5():49-56. PubMed ID: 3849425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.